A new extended release formulation (OROS®) of hydromorphone in the management of pain

Sharon M Weinstein
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USA

Abstract: Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects typical of opioid analgesics. There is a wide interindividual variability of responsiveness to exogenous opioids both in terms of analgesic efficacy and side effects. Optimizing pain management for the individual patient may require sequential trials of opioid medications until the regimen with the most favorable therapeutic ratio of efficacy to side effects is determined.

Keywords: analgesics, opioid, hydromorphone, OROS®, extended-release

Hydromorphone, a semi-synthetic opioid, is one of a family of closely related μ-agonist opioid drugs with dose-dependent analgesic properties. Hydromorphone has been used clinically to treat pain since the 1920s, and is commercially available in the United States in oral, rectal and injectible formulations.

A new formulation of extended release hydromorphone utilizing the OROS® technology has been demonstrated to provide sustained analgesia in patients with various types of chronic painful conditions. This new formulation may be advantageous to patients who tolerate hydromorphone well and other opioids poorly.

Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain.1–3 Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis.4–11 In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects typical of opioid analgesics.3 It is well known that there is a wide interindividual variability of responsiveness to exogenous opioids both in terms of analgesic efficacy and side effects. Optimizing pain management for the individual patient may require sequential trials of opioid medications until the regimen with the most favorable therapeutic ratio of efficacy to side effects is determined.

Hydromorphone

Hydromorphone, a semi-synthetic opioid, is one of a family of closely related μ-agonist opioid drugs with dose-dependent analgesic properties (Figure 1). Hydromorphone has been used clinically to treat pain since the 1920s,12 and is commercially available in the United States in oral, rectal and injectible formulations. Similar to other opioid agonists, hydromorphone does not have a ceiling effect for analgesia,3 and doses can be increased as needed to relieve moderate to severe pain. The relatively short duration of action of oral hydromorphone limits its use for persistent daily pain. Around-the-clock
For the treatment of acute post-operative pain, parenteral opioids such as patient controlled analgesia devices. In the setting of short term acute pain management, parenteral opioids such as hydromorphone are advantageous for rapid titration to analgesia and downward dose tapering as pain improves.

Hydromorphone has been used to treat acute and chronic pain in adults and children. It is routinely administered via the oral, rectal, intravenous, subcutaneous and spinal (epidural and intrathecal) routes. In studies of subcutaneous hydromorphone implants, it was demonstrated that drug was steadily released for weeks in vitro and in vivo, producing plasma levels comparable to subcutaneous infusion.15 There is no evidence that the abuse potential of hydromorphone differs from that of other opioids.16–18

There are several considerations in the choice of an initial opioid agonist medication and dosing schedule, including the personal history of efficacy and tolerability of different opioid analgesic medications.19 Prescribers should be familiar with the pharmacokinetics and pharmacokinetics of opioid analgesics. Patients with chronic painful conditions are usually best managed with a combination of sustained action and immediate release form of the same opioid drug, for control of “background” and “breakthrough” pain. Clinical pain management guidelines include procedures for converting from one route of drug administration to another and from one opioid analgesic agent to another. When converting hydromorphone from the parenteral to oral route one should use the potency ratio of 1.5:7.5 (conversion factor of 5). Oral and rectal routes of administration are considered equipotent for the purpose of opioid conversions. The intravenous, subcutaneous and intramuscular routes are considered equipotent.20,21

Although hydromorphone may confer some advantages, caution should be used when prescribing for patients with renal insufficiency, as there is a potential for toxicity due to accumulation of glucuronidated by-products.22,23

Published guidelines also include methods for calculating equianalgesic doses of the different opioid agonist drugs.3,13,19,24,25,26 For an initial opioid conversion, the use of a conservative dose is an appropriate strategy. Because of incomplete cross-tolerance among opioids,27 it is recommended that initial doses be reduced to 50%–75% of the calculated equianalgesic dose. After the initial conversion, upward dose titration is usually necessary to attain an adequate analgesic response.19,22,26,28 The data for the analgesic potency of hydromorphone compared to morphine are summarized in Table 1.

Single-dose comparison studies are an accepted method of establishing relative analgesic efficacy and potency, as well as onset, peak, and duration of analgesic effects.29,30 A well-controlled relative potency study of parenteral morphine and hydromorphone in patients with postoperative pain resulted in ratios of 8.3–11.1:1 (morphine significantly less potent than hydromorphone).31 The first study of the equianalgesic dose of morphine and hydromorphone in patients with cancer pain demonstrated an equivalence of parenteral morphine to hydromorphone of 7.9:1.32 Single-dose relative potency studies showed that oral morphine is 1/6 as potent as intramuscular (IM) morphine,33 that 10 mg of IM morphine is equianalgesic to 1.3 mg of IM hydromorphone,19 and that IM hydromorphone is 5 times more potent than oral hydromorphone, suggesting that 60 mg of oral morphine and 7.5 mg of oral hydromorphone are approximately equianalgesic. These results indicate a conversion ratio of 8:1 (morphine:hydromorphone) for the oral formulations. In a repeated-dose study in patients with cancer-related pain, controlled-release hydromorphone and controlled-release morphine administered every 12 hours provided equivalent analgesia at a conversion ratio of 7.5:1.34

In two controlled clinical studies of 344 patients that compared the efficacy and safety of hydromorphone hydrochloride extended-release capsules with hydromorphone hydrochloride immediate-release tablets in the treatment of persistent moderate to severe pain (cancer and noncancer related), a conversion ratio of 8:1 mg of oral morphine to oral hydromorphone was used.13,31,35

In a retrospective clinical study comparing hydromorphone to morphine potencies, the authors observed a
range of 3.7–5:1 (morphine to hydromorphone) depending on the direction of conversion, but independent of initial dose level.28 Additional studies have indicated that the conversion ratios may depend on the direction of conversion, that is, to or away from hydromorphone as summarized in Table 1. It is clear that hydromorphone is significantly more potent than morphine on a milligram for milligram basis, regardless of the conversion direction or route of administration.

It cannot be overemphasized that conversion ratios are meant as an initial approximation and that individual clinical circumstances influence the calculation of an opioid dose.4,13,19,26 Close monitoring of patients is generally recommended during further titration after the initial conversion from one opioid agonist to another.

Hydromorphone yields metabolites, especially the hydromorphone-3-glucuronide, that may contribute to excitotoxic neurologic states. With high dose administration, myoclonus and seizures may occur. The rare syndrome of hyperalgesia may manifest initially as worsening intensity of the pain syndrome and new, discrete allodynia in the saddle region (the author has observed this with high dose intrathecal administration). If these symptoms emerge, patients may respond to opioid rotation, dose reduction and administration of benzodiazepine.36,37,38

Modified-, controlled-, sustained- or extended-release formulations of opioids have been in clinical use for over 25 years. Such formulations of hydromorphone hydrochloride have been developed to provide sustained analgesia for patients requiring medication for the control of persistent daily pain. Consistent pharmacokinetics and pharmacodynamics have been demonstrated with formulations designed for every 12- and every 24-hour dosing in patients with cancer and noncancer related pain.35,39–46

Palladone™, a 24-hour hydromorphone product, was voluntarily withdrawn from the United States market by the manufacturer due to the potential for “dose dumping” when it was ingested simultaneously with alcohol, although no such adverse events were reported to have occurred during post-marketing surveillance.47,48

In summary, hydromorphone is a safe and effective opioid agonist analgesic for the management of acute and chronic pain of various etiologies in patients of all ages.

**Table 1 Relative analgesic potency of hydromorphone compared to morphine**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Potency ratio</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruera 46</td>
<td>3.6:1</td>
<td>Converting oral hydromorphone to morphine</td>
</tr>
<tr>
<td>Lawlor et al 28, Mercandante 61</td>
<td>3.7:1</td>
<td>Converting oral hydromorphone to morphine</td>
</tr>
<tr>
<td>Lawlor et al 28</td>
<td>4.3:1</td>
<td>Average</td>
</tr>
<tr>
<td>Lawlor et al 28</td>
<td>5:1</td>
<td>Converting oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Mercandante 61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruera 46</td>
<td>5.3:1</td>
<td>Oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Grilo 62</td>
<td>5.7:1</td>
<td>Oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Wirz 63</td>
<td>5:1</td>
<td>Oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Lee 35</td>
<td>7.7:1</td>
<td>Oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Wallace 64</td>
<td>5:1</td>
<td>Oral morphine to hydromorphone</td>
</tr>
<tr>
<td>Dunbar 65</td>
<td>3:1</td>
<td>Comparing intravenous use via patient controlled analgesia</td>
</tr>
<tr>
<td>Rapp 46</td>
<td>5:1</td>
<td>Intravenous patient controlled analgesia</td>
</tr>
<tr>
<td>Coda 67</td>
<td>5:1</td>
<td>Intravenous patient controlled analgesia</td>
</tr>
<tr>
<td>Collins 68</td>
<td>5:1</td>
<td>Pediatric; intravenous patient controlled analgesia</td>
</tr>
<tr>
<td>Miller 69</td>
<td>5:1</td>
<td>Subcutaneous at end of life</td>
</tr>
<tr>
<td>Hill 70</td>
<td>10:1</td>
<td>Intravenous morphine to hydromorphone</td>
</tr>
<tr>
<td>Mahler 31</td>
<td>8.3–11.1:1</td>
<td>Intravenous morphine to hydromorphone</td>
</tr>
<tr>
<td>Weinstein 45</td>
<td>8:1</td>
<td>Synthesis of previously published data applied in clinical trial of oral once-daily hydromorphone</td>
</tr>
</tbody>
</table>

*Data from oral and subcutaneous routes mixed.*

**OROS® hydromorphone**

OROS® is a patented technology for the osmotic-controlled release oral delivery of medication. OROS® has been reported to produce stable drug concentrations, uniform drug effects, reduced dosing frequency and an improved safety profile. A review of the technology development over
the past 30 years has indicated that there are four different systems: the elementary osmotic pump, the two-layer osmotic push-pull tablet, the advanced longitudinally compressed tablet multilayer formulation, and the L-OROS™ system. These systems have been applied in several different therapeutic areas. According to the manufacturer, OROS® technology employs osmosis to provide precise, controlled drug delivery for up to 24 hours, can be used with a range of compounds, and may enhance bioavailability due to more efficient drug absorption. There are currently thirteen OROS® commercial products available worldwide. In 2006, Jurnista™, a hydromorphone formulation utilizing the OROS® Push-Pull delivery system, was released in Europe after completing the European Mutual Recognition Program. Four dosage strengths will be available – 8, 16, 32 and 64 mg – for once-daily (every 24 hours) dosing.

Two studies of OROS® hydromorphone formulations have been recently reported. In one study, the pharmacokinetics of intravenous, oral immediate-release and oral extended-release (OROS®) formulations were compared. The OROS® formulation produced continuous release of medication over 24 hours, predicted to allow once daily dosing. The authors concluded that the formulation will produce less fluctuation in plasma concentrations compared with repeated immediate-release equivalent dosing and that the formulation should therefore provide more consistent analgesic effect. The OROS® formulation was noted to have greater bioavailability, possibly related to decreased first-pass effect or enterohepatic recycling of drug.

An open-label, repeated-dose, single-treatment study evaluated the outcomes associated with standardized conversion from prior opioid therapy to the OROS® hydromorphone in patients with chronic malignant or nonmalignant pain. Eligibility criteria included baseline oral morphine equivalent requirement of greater than or equal to 45 mg daily. Over 400 patients received study drug. Significant improvements in pain were noted with OROS® hydromorphone compared to prestudy medications. Adverse events were consistent with those expected, ie, side effects affecting primarily the gastrointestinal and central nervous systems.

Several studies have supported the safety and efficacy of this formulation in the treatment of cancer related and other acute and chronic painful conditions.

A recent report revealed that when ingested with alcohol, dissolution of OROS® hydromorphone was not significantly altered, ie, there was no “dose dumping.”

Conclusion
With extended-release hydromorphone formulations available, those patients who tolerate hydromorphone far better than other opioids will be able to be treated with single agent opioid pharmacotherapy in a safe and convenient manner. Further research will be needed to establish the cost-effectiveness and advantages of long term treatment with extended-release hydromorphone preparations, particularly the OROS® formulation. One German study anticipated cost-effectiveness of this formulation for the treatment of pain associated with osteoarthritis.

Given the prevalence of chronic painful conditions, the wide interindividual variability in responsiveness to opioids; and our aging population that will have an increasing need for safe and effective analgesics; broader clinical applications of new extended-release preparations of opioids can be anticipated. The OROS® hydromorphone will likely find a therapeutic niche in the treatment of those patients with chronic painful conditions who have a more favorable therapeutic response to hydromorphone compared to other opioids. Clinical practitioners are encouraged to familiarize themselves with the pharmacology of opioids and to follow established guidelines for the management of pain that emphasize individualized treatment for optimal therapeutic outcomes.

Disclosures
The author has no conflicts of interest to disclose.

References


